



## OvaScience to Present at Upcoming Conferences

May 16, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 16, 2013-- [OvaScienceSM](http://www.ovascience.com), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that the Company's management team will present at two upcoming conferences in May. The conference and OvaScience presentation details are as follows:

- UBS 2013 Global Healthcare Conference on Tuesday, May 21st 3 p.m. at the Sheraton New York Hotel in New York City.
- Deutsche Bank Securities 38th Annual Health Care Conference on Wednesday, May 29 at 2:50 p.m. at The Westin Boston Waterfront Hotel in Boston.

Live audio webcasts of the presentations can be accessed by visiting the Investor section of the Company's website at [www.ovascience.com](http://www.ovascience.com). Replays of the webcasts will be archived on the OvaScience website for two weeks following the presentation.

### About OvaScience

OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company's patented technology is based on the discovery of egg precursor cells (EggPC<sup>SM</sup>), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT<sup>SM</sup> aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience's team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit [www.ovascience.com](http://www.ovascience.com).

### Forward-Looking Statements

*This press release includes forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's product candidates, including AUGMENT. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "aim," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates, which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the "Risk Factors" section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.*

Source: OvaScience, Inc.

OvaScience, Inc.  
Theresa McNeely, 617-299-7356  
Head of Corporate Communications  
[tmcneely@ovascience.com](mailto:tmcneely@ovascience.com)